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Abstract 
Objective: This study aimed to i) observe longitudinal outcomes and progression in 
behavioural variant frontotemporal dementia, with respect to probable and possible 
behavioural variant frontotemporal dementia, in accordance with international 
diagnostic criteria and ii) identify features that may aid clinicians better prognosticate 
in cases of possible behavioural variant frontotemporal dementia. 
Methods: We followed 58 consecutive patients longitudinally over a 6-year period 
and classified these patients as possible, probable or definite behavioural variant 
frontotemporal dementia, at presentation and latest review. Clinical, pathology, 
genetic, neuropsychological and neuroimaging data were analysed to categorise 
patients, compare group differences, determine rates of progression and identify 
prognostic features in possible bvFTD. 
Results: At presentation, 38 patients fulfilled probable criteria and of these, 36 
remained probable or converted to definite over time. The remaining 20 patients 
satisfied possible criteria only and greater than one-half changed category over time, 
termed changers, and progressed on cognitive and functional measures. Most (eight, 
40%) of these harboured the C9orf72 expansion. A positive family history, memory 
impairment and clinical abnormalities at presentation appeared as key features of 
progression (p < 0.05). A continuum of neuropsychological scores, progression rates 
and atrophy severity emerged across patients in probable, possible, changer and non-
changer categories, with probable bvFTD patients exhibiting the most severe 
abnormalities. 
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Interpretation: Behavioural variant frontotemporal dementia can show variable 
progression over time. A detailed neurological assessment may identify key features 
of progression when faced with the difficult case of possible bvFTD, while a 
diagnosis of probable bvFTD is accurate in a clinical setting. 
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Introduction 
The past two decades have seen a revolution in the characterization of behavioural 
variant frontotemporal dementia (bvFTD), which culminated in the development of 
internationally accepted diagnostic consensus criteria for bvFTD in 2011 1. These 
criteria segment the diagnosis of bvFTD into three tiers of certainty; possible, 
probable and definite according to neuroimaging, genetic and pathological findings. 
These criteria correctly classified 90% of all bvFTD cases in a recent large 
clinicopathological study 2. 
Despite this progress, prognosis of bvFTD remains challenging. A number of patients 
without atrophy on MRI only satisfy criteria for possible bvFTD, and remain in this 
category for years. Some of these patients are described as ‘phenocopy’ cases; the 
hallmark features of which include normal neuroimaging, preserved activities of daily 
living, normal ability on a battery of cognitive tasks and lack of progression 3-6.  In the 
absence of pathological reports of phenocopy cases the underlying neuropathological 
changes remain unknown.  
The discovery of the C9orf72 genetic expansion added a level of complexity to the 
bvFTD diagnosis. Indeed, in the absence of genetic testing, many patients harbouring 
this gene expansion satisfy the diagnostic criteria for possible, but not probable 
bvFTD at first presentation. The wealth of case reports emerging, detailing protracted 
and indolent cases with apparently normal neuroimaging and relatively normal 
neuropsychological profiles, are testament to the complex nature of this expansion 7-9. 
It is not surprising that a number of these patients were considered to be ‘phenocopy’. 
So while considerable refinements in diagnostic criteria have been made, pieces of the 
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puzzle remain – how do we deal with ‘possible bvFTD’; how many ‘possible bvFTD’ 
cases evolve to probable or definite disease; and where does the C9orf72 expansion fit 
into current diagnostic criteria.  
With these questions in mind, the present study explored the outcomes in a large 
bvFTD cohort. Drawing on previous clinicopathological studies in bvFTD, we 
hypothesised that the majority of probable cases in the study would remain probable 
or become definite on the basis of post-mortem examination 10, 11. Possible bvFTD as 
a separate entity has not yet been studied, however we expected some to exhibit 
deficits on neuropsychological measures sensitive to frontal lobe dysfunction, in 
keeping with true bvFTD. Contrary to the recommendations of the international 
diagnostic criteria and in line with recent evidence that bvFTD patients experience a 
degree of amnesia we suspected that many of our patients would also exhibit memory 
deficits 12. 
This longitudinally recruited cohort is ideal to address these issues as each participant 
was subject to a detailed work-up that included comprehensive clinical assessment, 
neuropsychological test battery, neuroimaging, genetic testing and long-term follow-
up. 
 
Methods 
 
Patients 
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Each patient was assessed at FRONTIER Frontotemporal Dementia Research group 
between 2008 and 2013. Patients were included in the study if they satisfied criteria 
for possible, probable or definite bvFTD and if they were seen on at least two 
occasions over a two-year period or more to allow time for significant progression, or 
(2) seen over a one-year period with a change in diagnosis over this period 1. Patients 
with FTD and concurrent Motor Neuron Disease (FTD-MND) were excluded from 
the study, but those who developed MND as their disease progressed were included. 
Ethical approval for this study was obtained from the South Eastern Sydney and 
Illawarra Area Health Service and the University of New South Wales ethics 
committees. Participants, or their person responsible, provided informed written 
consent in accordance with the Declaration of Helsinki.  
Patients were classified as possible, probable or definite bvFTD according to 
international diagnostic criteria 1. The diagnosis was reviewed on two occasions: at 
presentation and most recent attendance. To meet possible bvFTD criteria three of six 
core behavioural features were present namely disinhibition, apathy, loss of 
sympathy/empathy, stereotyped/compulsive behaviors, a change in dietary preference 
towards sweet foods and a frontal dysexecutive cognitive profile with relative sparing 
of memory and visuospatial function. To reach probable bvFTD, criteria for possible 
was met with additional evidence of functional decline, as well as frontal or temporal 
abnormalities on MRI or Fludeoxyglucose (18F)-Positron emission topography. For 
the purpose of classification and to determine if atrophy was present, MRI scans were 
reviewed using a validated visual rating scale, which assessed the orbitofrontal cortex, 
anterior temporal poles and insular cortex according to previously published data 13, 14. 
Atrophy was rated on a Likert scale by a blinded rater (ED) after appropriate training 
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on an independent data set. Intra-class correlation coefficient to assess inter-rater 
reliability was very high (Cronbach’s alpha = .9). The scale ranged from 0 (no 
atrophy) to 4 (severe atrophy). A score of 0-1 denoted normal brain while 2-4 was 
considered abnormal. The criterion for ‘definite bvFTD’ stipulate that pathological 
findings at autopsy, or genetic findings during life must confirm the diagnosis. All 
patients underwent genetic testing for the C9orf72 expansion and then those with a 
negative result but with a positive family history were tested for the microtubule 
associated tau protein (MAPT) and progranulin (GRN) genetic mutations. Each 
patient was offered the opportunity to join the FRONTIER brain donor programme. 
Pathological evidence from all such brain donors who died during the period of the 
study was analysed and included in the present study.  
 
Clinical assessment 
Patients were assessed by an experienced behavioural neurologist and clinical 
information was recorded on a standardized proforma. Behavioural symptoms were 
systematically explored during the carer interview based upon the CBI (Cambridge 
Behavioural Inventory) 15 and corroborated by the carer based responses on the 
Neuropsychiatric Inventory (NPI) 16 which was completed prior to the visit. 
Neurological examination documented features of MND, aphasia, Parkinsonism, 
apraxia, ataxia and eye movement abnormalities.  
A family history was obtained and the Goldman score was calculated 17. A score of 
1 = at least three family members affected with diagnosed FTD and or MND over 
two generations with one person being a first degree relative of the other; 2 = three 
 8 
or more family members affected with dementia and/or MND but do not meet 
criteria for 1; 3 = at least one affected family member with confirmed FTD and/or 
MND or early onset dementia; 3.5 = one affected relative with unspecified or late 
onset dementia; 4 = no family history. A score of 3 or below was considered a 
positive family history. A family history of significant psychiatric illness in first-
degree relatives was also obtained. A significant family history was considered 
present if a psychiatric diagnosis (e.g. schizophrenia, schizotypal, delusional 
disorder, mood disorder) was made by a trained psychiatrist and was sufficient to 
require treatment and or impacted on functional ability.  
Global cognitive function was measured using the Addenbrooke's Cognitive 
Examination-Revised (ACE-R;18. Disease staging was assessed with the 
Frontotemporal Dementia Functional Rating Scale (FRS) 6. 
 
Neuropsychological assessment 
The cognitive assessment examined the integrity of the main cognitive domains, as 
well as emotion processing capacity. Episodic memory was tested using the 
delayed recall components of the Rey-Osterrieth Complex Figure test 19, 20 and the 
Rey Auditory Verbal Learning Test 21. Visuospatial ability was measured with the 
copy component of the Rey-Osterrieth Complex Figure test 19, 20. Working memory 
and executive functions were measured with the Digit Span Backwards test 22, the 
Hayling test of inhibitory response 23, Verbal Fluency (FAS) 24 and the Trail 
Making Test 25. Naming was assessed using the Sydney Language Battery 
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(SYDBAT) 26. Finally, emotion processing was assessed using The Awareness of 
Social Inference Test (TASIT) 27 and the Ekman 60 28 
 
Analysis of group differences on behavioural, clinical and neuropsychological 
measures 
Data was compared between 1) the entire bvFTD group and controls, 2) probable 
bvFTD and possible bvFTD and 3) possible bvFTD patients who became 
probable/definite, termed changers, and possible bvFTD cases who remained 
possible, termed non-changers. Age-matched healthy controls (n = 25) were selected 
from the FRONTIER voluntary control database.  
 
Genetic screening 
DNA was extracted from whole blood collected for genetic screening following 
informed consent and using protocols approved by the Human Research Ethics 
Committee of the South Eastern Sydney and Illawarra Area Health Service. The 
repeat primed PCR was performed using the procedure described previously 29, 
based on the protocol of Renton and colleagues 30. A patient's DNA sample was 
deemed positive for the C9orf72 repeat expansion if it contained an allele with > 
30 repeats. Patients with a family history were also screened for other common 
genetic mutations (GRN, MAPT) by Sanger sequencing of genomic DNAs 
corresponding to all coding exons 31, 32 
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Neuropathology 
Consent for brain donation for research was obtained for each case with tissue 
collection and processing performed by the Sydney Brain Bank according to 
protocols approved by the Human Research Ethics Committee of the University of 
New South Wales. Cases were systematically classified into the major molecular 
classes of frontotemporal lobar degeneration [FTLD-tau, FTLD-TDP (FTLD-
transactive response DNA binding protein of 43 kDa), FTLD-FUS (FTLD-fused in 
sarcoma), FTLD-UPS (FTLD-ubiquinated inclusion bodies) and FTLD-ni (FTLD 
without inclusions)]33 in addition to criteria for other neurodegenerative disorders 
34 using immunohistochemical techniques 35.  
 
Neuroimaging 
Imaging acquisition 
All participants underwent whole-brain T1 imaging using a 3T Philips MRI 
scanner with standard quadrature head coil (eight channels). The 3D T1-weighted 
sequences were acquired as follows: coronal orientation, matrix 256 x 256, 200 
slices, 1mm2 in-plane resolution, slice thickness 1mm, echo time/repetition time = 
2.6/5.8 ms.  
Voxel-based morphometry analysis 
Three-dimensional T1-weighted sequences were analysed with FSLVBM, a VBM 
analysis 36 and part of the FSL software package 
http://www.fmrib.ox.ac.uk/fsl/fslvbm/index.html. Tissue segmentation was carried 
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out using FMRIB’s Automatic Segmentation Tool (FAST) from brain-extracted 
images. The resulting grey matter partial volume maps were then aligned to the 
Montreal Neurological Institute standard space (MNI 152) using the non-linear 
registration approach using FNIRT, which uses a b-spline representation of the 
registration warp field. The registered partial volume maps were divided (to correct 
for local expansion or contraction) by the Jacobian of the warp field. These images 
were smoothed with an isotropic Gaussian kernel with a standard deviation of 
3mm (full-width at half-maximum: 8mm). A voxel-wise general linear model was 
applied and permutation-based non-parametric testing was used to form clusters 
with the Threshold-Free Cluster Enhancement method, tested for significance at 
<0.01 corrected for contrasts between bvFTD cohorts with a cluster-extent 
threshold of at least 50 contiguous voxels. A more lenient threshold was used for 
subgroup analysis  (< 0.05 corrected for patient subgroup versus controls and < 
0.01 uncorrected for between patient group comparisons) to increase the statistical 
power. Contrasts were corrected for Family wise error (FWE).  
 
Statistical analysis 
Data were analysed using SPSS 22.0 statistical package. Kolmogorov-Smirnoff 
tests were applied to determine if variables were normally distributed. Parametric 
variables were compared across groups via independent t-tests and analysis of 
variance (ANOVA). Non-parametric data were analysed using Mann-Whitney and 
the Kruskal-Wallis tests, and categorical data were compared with Chi-Square 
tests. Linear mixed effects models were built to examine the change in 
performance across groups, over time 37.The fixed effects of the model included 
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diagnostic category, follow-up time (calculated as days from first ACE-R 
assessment) and the interaction between diagnostic category and follow-up time. 
The only random effect modeled was the individual variability associated with the 
participants at baseline, using the random intercept model. A significant effect of 
follow-up time indicates that performance on the variable of interest changes 
linearly over time, averaged across groups. A significant interaction between 
diagnostic category and follow-up time indicates that the rate of change (slope) 
differs according to diagnosis. 
 
Results 
 
Participants, genetics and neuropathology – the entire bvFTD cohort 
Of 89 patients with bvFTD who were seen at the clinic over the study period, 58 met 
inclusion criteria. Of the 31 patients who failed to meet inclusion criteria, due to lack 
of sufficient follow-up, 12 were probable cases and 19 were possible bvFTD cases. 
The 12 probable cases had either passed away without autopsy or were too severely 
impaired for follow-up. Of the 19 possible cases five had moved to a distant location 
and 14 were uncontactable many of whom had complex family issues when seen at 
first presentation. Follow-up ranged from 1 to 5.2 years with a mean follow-up period 
of 3.1 years. Demographic data are represented in Table 1. 
The C9orf72 expansion was present in 15 patients, representing 30% of the entire 
cohort. Based on the Goldman score, a positive family history was present in 18 
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(31%) of the total cohort (Table 2). Of these familial cases, the C9orf72 expansion 
was present in 10 (55%), a GRN mutation in five (28%) and a MAPT mutation in one 
(6%). Known genes were not present in two familial cases (11%). Five patients with 
apparently sporadic disease, representing 12.5% (five of 40) of the sporadic cases 
harbored the C9orf72 expansion. Three of these patients had a positive family history 
of significant psychiatric disease, which was present in six (40%) of the entire 
C9orf72 cohort. When the diagnostic criteria for bvFTD were applied, 20 met criteria 
for possible bvFTD and 38 patients met criteria for probable bvFTD. 
** Insert (Table 1) here 
Of the 38 probable cases, almost a half (17, 47%) became definite at follow-up, while 
a half (19, 50%) remained probable at follow-up and two (6%) had confirmed 
Alzheimer’s disease pathology at autopsy (Figure 1). C9orf72 expansions were found 
in both familial (n = 5) and sporadic disease (n = 2). A family history of psychiatric 
disease was present in one of two patients with apparently sporadic disease. In two of 
13 (15%) familial cases, no known gene was found. Three probable cases developed 
clinical and neurophysiological evidence of MND. 
In the possible bvFTD group, failure to meet criteria for probable bvFTD at 
presentation was due to a lack of imaging abnormalities, based on the visual atrophy 
rating scale and FDG-PET in all cases. Each patient displayed a degree of functional 
decline. Among the 20 possible bvFTD cases at baseline, 11 changed category over 
time to become probable or definite cases (labeled here ‘changer’; Figure 1). Of these, 
eight (80%) were found to harbour the C9orf72 gene expansion, five of these had a 
positive family history of dementia. In other words, all five patients with a positive 
family history in the ‘changer’ group harboured the C9orf72 gene expansion. Two of 
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the remaining three sporadic cases had a family history of psychiatric disease. The 
final three cases in the ‘changer’ group were diagnosed with ‘probable bvFTD’ 
following the development of brain atrophy on MRI. Mild to moderate brain atrophy 
on MRI was also observed in five of eight individuals with C9orf72 expansion at 
follow-up. The remaining nine possible bvFTD cases at baseline remained in the same 
diagnostic category at follow up (here labeled as ‘non-changer’). None of the bvFTD 
non-changers had a significant family history of neurodegenerative disorders. 
** Insert (Figure 1) here. 
 
Comparison of bvFTD and controls 
Clinical and neuropsychological assessment  
Abnormalities on clinical examination were present in over one-quarter of bvFTD 
patients and almost one-third had a positive family history. A detailed carer interview 
and NPI data revealed high rates of core behavioural symptoms in bvFTD 
participants. (Figure 2). BvFTD patients scored poorly across the range of 
neuropsychological tests compared to controls.  
** Insert (Figure 2) here 
 
Neuroimaging analysis – voxel-based morphometry atrophy analysis 
Overall bvFTD patients showed widespread atrophy in the dorsolateral prefrontal 
cortex, temporal poles, insular cortex, thalamus and striatum based on VBM analysis 
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(p < 0.01 corrected; Table 2). Atrophy was also present in posterior structures 
including occipital and parietal regions as well as the cerebellum. 
** Insert (Table 2) here 
 
Comparison of probable and possible bvFTD 
 
Clinical assessment 
Abnormal clinical findings on neurological examination were present in both probable 
(n=11) and possible (n=5) bvFTD patients (p > 0.05). The groups showed similar 
rates of family history positivity. Stereotypic/compulsive behaviours were more 
prevalent in the probable group  (p < 0.05), while other behavioural features were 
similar across the groups (Figure 2). 
 
Neuropsychological assessment  
On a group level, probable bvFTD patients exhibited significantly poorer performance 
across all cognitive domains except for naming (p > 0.1), than possible bvFTD 
patients (p < 0.05; Table 3). Compared to controls both probable and possible bvFTD 
patients showed significant cognitive impairment. 
**Insert (Table 3) here 
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Longitudinal data  
On a measure of global cognitive function, the ACE-R, the groups combined showed 
significant deterioration over time (p < 0.001) with a significant interaction between 
disease group and time (p < 0.05) indicating a faster rate of decline in probable 
bvFTD compared to possible bvFTD (Figure 3). On a measure of functional 
disability, the FRS, the group as a whole showed significant deterioration over time (p 
< 0.001), however no significant interaction between disease group and time (p 
<0.001) was identified indicating a similar rate of decline in both groups. 
**Insert (Figure 3) here 
 
Neuroimaging – voxel-based morphometry atrophy analysis 
Figure 4 demonstrates widespread atrophy in frontal regions including the dorsolateral 
prefrontal cortex, temporal lobes and subcortical structures in probable bvFTD 
compared to controls and corrected at p < 0.01. Posterior regions of the parietal and 
occipital cortex were also involved.  
Possible bvFTD patients showed similar regions of atrophy with a number of clusters 
found in posterior and subcortical regions including the cerebellum. Comparison 
between probable and possible bvFTD showed more atrophy in the probable group in 
frontal and subcortical regions while there were no areas of significant atrophy in the 
converse (Table 4).  
**Insert (Table 4) and (Figure 4) here 
 17 
 
Comparison of changers vs. non-changers 
 
Clinical assessment 
Abnormal clinical findings on neurological examination were found in the changer 
group only (p < 0.05; Parkinsonism n = 3, frontal release signs n = 2). The groups  
differed on the presence of stereotypic/compulsive behaviours with changers showing 
more abnormal behaviour than non-changers (p < 0.05, Table 2). Based upon a 
Goldman score, five of the changers, all of whom carried the C9orf72 mutation, had a 
positive family history of neurodegeneration (MND n = 4, FTD n = 1) in comparison 
to none of the non-changers (p < 0.01).  
 
Neuropsychological assessment (Table 5) 
Changers vs. controls 
In comparison to controls, and in keeping with the bvFTD profile of cognitive 
function, the changers scored significantly worse across the range of cognitive tasks 
(all p values < 0.05).  
Changers vs. non-changers 
The groups differed on components of the ACE-R namely memory and the total 
ACE-R score (p < 0.05). The most striking difference between groups was in episodic 
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memory. All aspects of memory differed significantly between groups including 
visual, verbal and recognition memory with changers scoring significantly worse than 
non-changers (p < 0.05).  
On some tests of executive function there was evidence for poorer performance in 
changers compared to non-changers but findings were inconsistent across tasks.  
Visuospatial functioning, emotion processing and naming scores did not differ 
significantly between changers and non-changers (p > 0.2). 
Non-changers vs. controls 
The profile in non-changers versus controls was variable for executive tasks and 
emotion processing but the non-changers consistently scored in the control range 
across the memory indices.  
** Insert (Table 5) here 
 
Longitudinal data – Do the changers deteriorate over time? 
As expected, on a measure of global cognitive function, the ACE-R, the groups 
combined showed significant deterioration over time (p < 0.05) with a significant 
interaction between disease group and time (p < 0.05) indicating a faster rate of 
decline in the changers compared to non-changers (Figure 5). Similarly on a measure 
of functional disability, the FRS, the group as a whole showed significant 
deterioration over time (p < 0.001) with a significant interaction between disease 
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group and time (p <0.001) indicating a faster rate of decline in the changers compared 
to non-changers. Notably, non-changers remained stable on both measures. 
** Insert (Figure 5) here 
 
Neuroimaging – voxel-based morphometry atrophy analysis  
Figure 6 displays the patterns of atrophy at presentation in changers and non-changers 
in comparison to healthy control participants, corrected for Family Wise Error (FWE) 
at p < .05). The changers showed widespread atrophy predominantly in the anterior 
insula, striatum, orbitofrontal cortex and temporal poles with a left sided 
predominance (Table 6). These patterns of atrophy largely replicate those reported 
previously in bvFTD and C9orf72 mutation carriers. In contrast the non-changers 
showed minimal frontopolar atrophy only, in comparison to controls. Given the small 
sample sizes we used a less conservative threshold for between patient group 
comparisons. Direct comparisons between changers and non-changers revealed 
greater thalamic, anterior right insula, hippocampal as well as dorsolateral prefrontal 
cortex volume loss in the changer group (p < 0.01 uncorrected), compared to non-
changers.  
** Insert (Table 6) and (Figure 6) here 
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Discussion 
This novel study provides fresh insights into the progression of possible bvFTD over 
time. The results of this study show two distinct trajectories for possible bvFTD 
patients. The first group, referred to as changers, deteriorate cognitively and 
functionally over time and are likely to carry the C9orf72 expansion, while the second 
group, termed non-changers, remain stable over a number of years. The chance at 
presentation of following either trajectory is almost 50:50 but a number of predictive 
features have been identified. Family history of neurodegeneration, clinical 
abnormalities on examination, stereotypic and ritualized behaviours, and deficits on 
the ACE-R are associated with progression, with memory deficits also emerging as a 
marker of progression. Our results indicate that the likelihood of progression may be 
determined during a routine neurological consultation by means of a detailed clinical 
interview, examination and a brief test of global cognition. Brain atrophy analyses 
show subtle but widespread cortical atrophy in changers when compared to non-
changers, in keeping with true bvFTD in the changer group. Notably, a probable 
bvFTD diagnosis in the clinic is accurate. Finally, a continuum of neuropsychological 
and neuroimaging abnormalities are seen across probable bvFTD, possible bvFTD, 
changers and non-changers, with most severe changes seen in probable bvFTD. 
To firstly consider the possible cases, one–third of the entire cohort fell into this 
category at presentation. They exhibit key behavioural features of bvFTD yet show 
little, or no, atrophy on MRI as judged using a visual rating scale. This raises the 
question of whether such patients have neurodegenerative conditions. Although the 
sample size is relatively small and validation in a larger independent centre is 
desirable, it is nonetheless striking that almost one half of all possible cases were 
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C9orf72 positive, and all possible cases with a family history of neurodegeneration 
carried this mutation. A positive family history together with abnormalities on clinical 
examination emerge as robust clinical indicators of progression in this group. A 
careful clinical history to unearth a family history of a neurodegenerative disorder, 
especially MND, clinical examination and cognitive evaluation could identify the 
majority of cases likely to progress, many of whom harbour the C9orf72 mutation, 
and may guide clinicians to appropriately identify patients for referral to genetic 
services. It should be remembered that genetic testing is not always easily accessible 
for clinicians as hospital budgets may not accommodate genetic screening testing or 
laboratories may not have the technology.  It is also notable that a half of cases with 
this mutation initially only met criteria for possible rather than probable bvFTD. 
Memory, traditionally considered to be unimpaired in bvFTD, appears as a hallmark 
neuropsychological deficit in the changer group. Not only is memory impaired but the 
deficit spans a variety of memory components. This is perhaps testament to the true 
nature of neurodegeneration in this group. Memory impairment in bvFTD is not a new 
concept 12. A recent study compared memory scores in patients with true bvFTD to 
‘phenocopy’ cases 38. Similar to our data they identified a number of memory 
measures to distinguish true bvFTD from ‘phenocopy’ cases. This has been further 
corroborated in a study that identified two distinct amnestic profiles in bvFTD; one 
with severe memory deficits comparable to Alzheimers disease and another with 
subnormal and normal memory scores 39. Bearing in mind that the majority of 
changers harbored the C9orf72 mutation it is compelling that previous studies 
comparing C9orf72 and sporadic bvFTD linked memory problems to mutation 
carriers 40. In another study memory deficits were found to be comparable in both 
sporadic and C9orf72 bvFTD but the underlying neural correlates differed between 
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the groups 41. Our data indicates that of all cognitive assessments memory tests may 
best distinguish possible cases likely to progress from those who will remain stable 
over a number of years. In contrast, performance on executive tasks appears more 
variable and does not discriminate changers from non-changers. 
This raises the fundamental question: what is the underlying abnormality in the non-
changers? They show mild deficits on tests previously found to be sensitive markers 
of bvFTD such as inhibitory control and emotion processing 42. Previously patients 
with little or no progression over years and normal imaging have been referred to as 
‘phenocopy cases’3-5. These patients are predominantly male and present with a 
collection of behavioural features indistinguishable from true bvFTD. It has been 
hypothesized that this presentation represents a decompensated developmental 
disorder in the Asperger-Autism spectrum appearing in later life. The results from the 
present study may partly corroborate this theory as mild executive impairments are 
seen in both non-changers and patients on the Asperger’s/Autism spectrum 43. 
Similarly emotion recognition is impaired in non-changers and can also be altered in 
the Asperger’s/Autism spectrum 44. A comparison study between these two groups 
may shed further light on this concept but unfortunately was beyond the scope of this 
study. The lack of significant atrophy on imaging also appears to support these 
theories although little is known of the functional, pathological and neurochemical 
processes at play. It remains possible that a proportion of such cases may have a 
sporadic form of neurodegeneration with extremely slow progression although this 
seems unlikely. 
On a neuroanatomical level, our data suggests that while non-changers do not exhibit 
clear atrophy on visual inspection of MRI, there is subtle but significant widespread 
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atrophy present. The atrophy pattern is similar to that found in typical bvFTD and 
involves regions involved in memory and executive tasks 45, 46. The thalamus has been 
highlighted in C9orf72 imaging studies and is a key component in memory with links 
to an extended hippocampal circuit. In keeping with other studies, our data identified 
significant thalamic atrophy in the changers that accords well with their cognitive 
profile. The disparity between atrophy seen on automated VBM group studies and 
visual inspection of individual scans is concerning. Given the barriers to developing a 
quantifiable measure of individual grey matter integrity, physicians would be advised 
to be aware of bvFTD in the presence of an apparently normal MRI. Clearly more 
sensitive but clinically applicable methods of detecting subtle brain atrophy are 
required. 
Subgroup analyses reveal a disassociation in progression between functional and 
cognitive abilities in probable as compared to possible bvFTD. Despite a similar 
length of illness, probable bvFTD patients show worse cognitive deficits at 
presentation and progress more rapidly than possible bvFTD patients. In contrast, 
although the possible group was less functionally impaired at presentation, the two 
groups deteriorate at a similar rate. This may be explained by previous work which 
suggests that cognitive assessment alone does not account for disease severity and 
progression in bvFTD 6. In contrast, there was a clear lack of progression in non-
changers over time, coupled with a lack of atrophy on MRI at follow-up. Longitudinal 
neuroimaging studies but may offer insight into the impact of functional versus 
cognitive changes in bvFTD over time. 
Turning next to probable bvFTD. Within our cohort the diagnostic accuracy for 
probable bvFTD was high. Keeping in mind that these results have been generated 
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from a specialist FTD centre, they nevertheless suggest that physicians can be 
confident when they diagnose probable bvFTD, if current diagnostic criteria are 
applied. It is unsurprising that despite having behavioural, executive and imaging 
findings in keeping with bvFTD that 12% of probable cases had Alzheimer’s disease 
pathology at autopsy. The clinical overlap between bvFTD and Alzheimer’s disease 
with predominant frontal lobe pathology has long been recognized. Unfortunately the 
ability to distinguish between the two during life can be difficult but may become 
easier as nuclear imaging identifying beta-amyloid in brain tissue becomes more 
widely available 47. The need to make this distinction will become more pressing if 
pathology-based pharmacological therapy becomes available.  
As in other studies of bvFTD, C9orf72 is the most common gene abnormality and 
together with GRN and MAPT mutations account for the majority of familial disease. 
There remains, however, a minority of familial cases without a known gene defect 
while the C9orf72 mutation is also present in a number of apparently sporadic cases. 
A locus on chromosome 16p12.1-q12.2 has been linked to familial cases of FTD, 
particularly FTD-MND cases, which are negative for any of the known genetic 
mutations, suggesting that this region may harbour another genetic mutation for FTD 
48.  Previous studies have shown that familial psychiatric illness is associated with 
C9orf72 49, 50, and we have demonstrated that when familial mental health disorders 
are considered as evidence of neurodegeneration the majority of sporadic cases can be 
accounted for.  
Together these results have repercussions for the reliability of current diagnostic 
criteria, which state that to conform to the cognitive profile of bvFTD there should be 
‘relative sparing of episodic memory’. Imaging abnormalities must also be present to 
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meet probable criteria. Contrary to current recommendations, this study and numerous 
others have found that memory deficits in bvFTD are often present and comprise an 
important component of the phenotype. Finally, important information can be gleaned 
from the routine neurological consultation and clinicians should consider this when 
faced with difficult questions of prognosis and referral for genetic testing.  
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Figure Legends 
 
Figure 1: Flowcharts demonstrate the change in diagnosis over time for cases of 
probable bvFTD (Figure 1A) and possible bvFTD (Figure 1B) at presentation. 
 
Figure 2: Behavioural features across the spectrum of bvFTD expressed as 
percentages of the total group. * p < 0.05 
 
Figure 3: 3A demonstrates estimated marginal means based on the % change in 
ACE-R score across time for probable and possible bvFTD.  Time (p < 0.05). Time x 
Diagnosis (p < 0.05). 3B demonstrates estimated marginal means based on the change 
in Functional Rating Scale (FRS) Rasch scores across time.  Time (p < 0.001). Time x 
Diagnosis (p < 0.001). Error bars show 95% confidence intervals. 
 
Figure 4: Results from voxel-based morphometry analyses demonstrating areas of 
grey matter density decrease for i) probable vs control (a-c - red), ii) possible vs 
control (d-f – yellow) and iii) probable vs possible (g-i – blue). Clusters are overlaid 
on the MNI standard brain (MNI152_T1_2mm_Brain). Coloured voxels show regions 
significant in the analyses for p < 0.01 corrected. 
 
Figure 5: 5A demonstrates estimated marginal means based on the % change in 
ACE-R score across time for changers and non-changers.  Time (p < 0.05). Time x 
Diagnosis (p < 0.05). 5B demonstrates estimated marginal means based on the change 
in Functional Rating Scale Rasch scores across time. Time (p < 0.001). Time x 
Diagnosis (p < 0.001). Error bars show 95% confidence intervals. 
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Figure 6: Results from voxel-based morphometry analyses demonstrating areas of 
grey matter density decrease for i) changers vs controls (a-c), ii) non-changers vs 
controls and iii) changers vs non-changers. Clusters are overlaid on the MNI standard 
brain (MNI152_T1_2mm_Brain). Coloured voxels show regions that were significant 
in the analyses for p < 0.05 corrected for between group comparisons and p < 0.001 
uncorrected for between group comparisons. 
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Table 1. Demographics - Mean (standard deviation) scores for bvFTD patients vs. controls, probable vs. possible and changers vs. non-changers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
n.s. = non significant; *** = p < 0.001; ** = p < 0.01, *= p < 0.05 
ACE-R = Addenbrookes Cognitive Examination – Revised 
FRS = Functional Rating Scale 
 
 
Demographic data bvFTD Controls p values Probable Possible p values Changers Non-changers p values 
N 58 25 - 38 20 - 11 9 - 
Sex (M:F) 46:12 14:11 n.s 28:10 18:2 n.s 9:2 9:0 n.s 
Age at onset (years) 58.5 (7.9) - - 59.1 (8.2) 57.4 (4.2) n.s 55.2 (8.2) 58.4 (8) n.s 
Education (years) 12 (3.1) 13.4 (2.3) n.s 12.5 (3.2) 10.8 (2.7) n.s 10.2 (1.7) 10.3 (2.8) n.s 
Disease Duration 
(years) 
4.5 (3.0) - - 3.5 (2.4) 5.4 (3.6) n.s 5.7 (3.6) 5 (3.5) n.s 
ACE-R (max 100) 76.1 (13.7) 94.5 (3.0) *** 72.4 (14.9) 83 (8) * 80.3 (7.1) 86.1 (6.3) ** 
FRS Rasch Score -0.5 (1.4) - - -0.7 (0.2) 0.2 (0.3) ** .3 (1.2) .3 (.7) n.s 
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Table 2. Voxel-based morphometry results for entire bvFTD cohort vs. control corrected at p < .05, at a cluster threshold of greater than 50 contiguous voxels. No 
significant clusters for control vs. bvFTD. 
 
 Regions 
Hemisphere 
(L/R/B) 
MNI coordinates for voxels 
of maximal intensity 
No. of 
voxels 
T value 
 X Y Z 
Cerebellum, insula, temporal lobe; hippocampus, 
opercular cortex, basal ganglia, thalamus, amygdala, 
heschl's gyrus, precuneus cortex, prefrontal cortex, 
anterior cingulate cortex, calcerine cortex, occipital pole, 
lateral occipital cortex, middle and inferior frontal gyri, 
angular gyrus, supramarginal gyrus, orbitofrontal cortex, 
frontal pole 
 
B 42 -62 -58 101453 2 
Precentral gyrus R 16 -16 40 54  
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Table 3: Neuropsychological test results in probable bvFTD, possible bvFTD and controls.  
Domain Cognitive Test Sub-test Scores (Mean) SD P values 
Probable Possible Controls Prob vs. Poss Prob vs Con Poss vs 
Con 
General ACE-R 72.4 (14.9) 83 (8) 94.5 (3.1) 0.01 < 0.001 < 0.001 
Executive TMT -Time difference 146.8 (98.9) 95.2 (62.4) 76.1 (32) 0.05 < 0.001 < 0.001 
Digit Span-Backwards 3.5 (1.4) 4.2 (1.2) 5.4 (1.2) 0.05 < 0.001 < 0.001 
Hayling Cat A errors 7.2 (5) 2.4 (2.5) .14 (.4) < 0.001 < 0.001 < 0.001 
Cat B errors 2.6 (2.4) 2.8 (2.2) 1 (1) 0.59 0.01 < 0.001 
Letter Fluency 7.5 (3.7) 9.0 (5.3) 13.1 (3.2) 0.23 < 0.001 < 0.001 
Memory RAVLT Immediate 4.8 (3.9) 7.3 (3.3) 9.6 (2.7) 0.04 0.04 0.03 
Delayed 4.6 (4) 6.3 (3.8) 10 (2.3) 0.15 < 0.001 < 0.001 
RCF: 3 min recall 6.6 (6.1) 12.6 (7.1) 18 (6) 0.01 < 0.001 0.02 
Doors: Combined 5.9 (7.6) 12.3 (8.2) 19 (15) 0.01 < 0.001 < 0.001 
Visuospatial RCF: Copy score 28 (5.5) 25.8 (6.7) 32 (3.3) 0.23 < 0.001 < 0.001 
Emotion Ekman 60 33 (9.7) 40.3 (6.1) 49.3 (4.2) 0.01 < 0.001 < 0.001 
Tasit 13.5 (5.8) 18.9 (3.3) 24 (1.8) < 0.001 < 0.001 < 0.001 
Language Sydbat - Naming 19.9 (6.4) 23.1 (3.1) 27 (2) 0.18 < 0.001 < 0.001 
 
 
 
  
Significant values at p < 0.05 indicated in bold. 
ACE-R = Addenbrookes Cognitive Examination – Revised. TMT = Trail Making Task. RAVLT = Rey Auditory Verbal Learning Test. RCF = Rey-Osterrith 
Complex Figure. Sydbat = Sydney Language Battery. Prob =Probable, Poss=Possible, Con = Control 
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Table 4. Voxel-based morphometry results for probable vs. possible bvFTD, corrected at p < .05, at a cluster threshold of greater 
than 50 contiguous voxels. No significant clusters for possible vs. probable bvFTD. 
 
Regions Hemisphere 
(L/R/B) 
MNI coordinates for voxels No. of 
voxels 
T value 
of maximal intensity 
  X Y Z   
Probable vs. possible      2 
       
Parahippocampal gyrus, hippocampus, amygdala, 
temporal fusiform cortex, planum polare, insula, 
superior, middle and inferior temporal gyrus, temporal 
pole, orbitofrontal gyrus, caudate, accumbens, caudate, 
frontal and central operculum cortex, heschls gyrus 
R 28 -16 -24 5844  
       
Superior, inferior and middle temporal gyrus, 
hippocampus, parahippocampal gyrus, amygdala, 
insula, orbitofrontal cortex, caudate, putamen, temporal 
pole, frontal operculum cortex, subcallosal cortex 
R -56 -16 -10 5739  
       
Frontal pole, frontal medial cortex, paracingulate gyrus B 10 56 -2 1798  
       
Inferior temporal gyrus L -58 -48 -28 176  
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Table 5: Neuropsychological test results in changers, non-changers and controls 
Domain Cognitive 
Test 
Sub-test Scores (Mean) SD p values 
Changers Non-Changers Controls Chg vs Non-Chg Chg vs Con Non-Chg vs Con 
General ACE-R 78.4 (7.5) 87 (6.6) 94.5 (3.1) 0.01 < 0.001 < 0.001 
Executive TMT - Time difference 129.9(62.4) 108.7 (55.2) 76.1 (32) 0.02 < 0.001 0.1 
Digit Span Backwards 3.8 (0.9) 4.4 (1.5) 5.4 (1.2) 0.24 < 0.001 0.08 
Hayling Cat A errors 4.7 (4.5) 1.3 (1.6) .14 (.4) 0.04 < 0.001 0.03 
Cat B errors 2.9 (2.6) 2.4 (1.7) 1 (1) 0.8 0.04 0.04 
Letter Fluency 8.1 (4.4) 9.8(5.9) 13.1 (3.2) 0.9 0.04 0.04 
Memory RAVLT Immediate  7 (2.7) 10 (4) 10 (2.3) 0.11 0.04 0.5 
Delayed  5.7 (3.6) 10.7 (3.4) 9.6 (2.7) 0.03 0.04 0.5 
RCF: 3 min recall 8.7 (5.7) 15.5 (6.7) 18 (6) 0.02 < 0.001 0.35 
Doors: Combined 6.9 (8.3) 16 (6.3) 19 (15) 0.02 < 0.001 0.07 
Visuospatial RCF: Copy score 25 (6) 27 (7) 32 (3.3) 0.36 < 0.001 < 0.001 
Emotion Ekman 60 39 (5.8) 41.5 (6.3) 49.3 (4.2) 0.2 < 0.001 < 0.001 
Tasit 19 (3.4) 18.6 (3.3) 24 (1.8) 0.8 < 0.001 < 0.001 
Language Naming 23 (2.7) 23.4 (3.5) 27 (2) 0.7 < 0.001 0.03 
 
Significant values at p < 0.05 indicated in bold. ACE-R = Addenbrooke’s Cognitive Examination – Revised. TMT = Trail Making Task. RAVLT = Rey Auditory Verbal Learning Test. RCF 
= Rey-Osterrith Complex Figure. Sydbat = Sydney Language Battery. Chg –changer. Non-chg –non-changer. Con = Control 
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Table 6. Voxel based morphometry results for changers vs controls and non-changers vs controls corrected at p < .05, and changers 
vs non-changers and non-changers vs changers uncorrected at p < 0.01, at a cluster threshold of greater than 50 contiguous voxels.  
 
 Regions 
Hemisphere 
(L/R/B) 
MNI coordinates for 
voxels  
of maximal intensity 
No. of 
voxels 
T value 
 X Y Z 
Changers vs. controls       
Temporal pole, orbitofrontal cortex, insula, 
putamen 
L 40 12 -6 663 2 
Insula, opercular cortex, inferior frontal gyrus 
putamen 
R 40 12 2 610  
Insula, opercular cortex L -30 10 8 200  
Occipital pole L -6 -90 14 117  
Occipital pole, orbitofrontal gyrus L -16 32 -22 63  
Middle and superior temporal gyrus L -50 -14 -14 53  
Inferior frontal gyrus L -56 22 2 51 
Non-changers vs. controls      
Frontal pole R 20 66 14 222 2 
Changers vs. Non-changers       
Insula, opercular cortex, putamen R 26 18 -4 848 2 
Thalamus R -16 -20 4 188  
Thalamus, hippocampus L 10 -32 14 61  
Middle frontal gyrus L -30 24 34 61  
Middle frontal gyrus L -32 4 44 51  
Non-changers vs. changers       
Cerebellum B 0 -48 14 135 2 
 
